Document is current

Article History

Received: 19 November 2024

Accepted: 9 January 2025

First Online: 23 January 2025

Declarations

:

: A. Campanati has served as consultant/advisor, received speaker honoraria and/or grants, and/or is investigator Abbvie, Galderma, Celgene, Janssen-Cilag, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, UCB, Almirall, Sanofi-Aventis, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte; M Burlando has acted as speaker or advisory board member for Abbvie, Amgen, Leo-pharma, Eli Lilly, Novartis, UCB, Almirall; E. Cozzani has acted as speaker or advisory board member for Abbvie, Amgen, Leo-pharma, Eli Lilly, Novartis, UCB, Almirall; K. Hansel has acted as investigator and speaker for Abbvie, Almirall, Amgen, Novartis, and Sanofi; L. Stingeni has acted as investigator and speaker for Abbvie, Almirall, Amgen, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi; L. Bianchi has acted as speaker or advisory board member for Abbvie, Leo-Pharma, Eli Lilly, Novartis, Pfizer, UCB, Almirall, Sanofi-Aventis, Biogen, Bristol, Boehringer, Johnson & Johnson; M. Galluzzo acted as a speaker and/or consultant for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis, and Sanofi; he has participated in clinical trials for AbbVie, Almirall, Boehringer-Ingelheim, Eli-Lilly, Incyte, Johnson & Johnson, Leo Pharma, Novartis and Sanofi.; M. Esposito has served as consultant/speaker from Abbvie, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, UCB, Sanofi/Regeneron; MC Fargnoli has served as consultant/advisor, received speaker honoraria and/or grants, and/or is investigator for AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, LEO Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma, Takeda; M. Megna has acted as a speaker or consultant for Abbvie, Amgen, Almirall, BMS, Boehringer, Leo-pharma, Eli Lilly, Janssen, Novartis, UCB; A. Balato has acted as speaker or advisory board member for Abbvie, Amgen, Almirall, BMS, Boehringer, Leo-pharma, Eli Lilly, Novartis, Pfizer, UCB, Sanofi. Federico Diotallevi, Pietro Quaglino, Luca Mastorino, Claudio Feliciani, Lucia Gallo, Agostina Legori, Giuseppe Argenziano, Federico Bardazzi, Paolo Gisondi, Francesco Bellinato, Tommaso Bianchelli, Giovanni Marco D’Agostino, Giulia Matacchione have no conflict of interest to declare. Anna Campanati is an Editorial Board member Dermatology and Therapy. Anna Campanati was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. All authors read and approved the final version of the manuscript.

: The patients in this manuscript have given written informed consent to publication of their case details. IRB approval was waived, the study was conducted respecting the Declaration of Helsinki, and all patients signed an informed consent before starting the study.